# SyncAV Post-Market Trial

Study · id `cardio:ct-nct04100148` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04100148](<https://clinicaltrials.gov/study/NCT04100148>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04100148

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1686 participants.

## Technical summary

Registry record NCT04100148. Randomized; no masking; primary purpose treatment. Start 2019-10-03 (actual); primary completion 2026-05-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 1686 participants (enrolled count; ClinicalTrials.gov record NCT04100148, source copy `cardio:ctgov-nct04100148-2025-12-18`, retrieved 2026-10-26)
- Started: 2019-10-03 (actual) (ClinicalTrials.gov record NCT04100148, source copy `cardio:ctgov-nct04100148-2025-12-18`, retrieved 2026-10-26)
- Primary completion: 2026-05-31 (anticipated) (ClinicalTrials.gov record NCT04100148, source copy `cardio:ctgov-nct04100148-2025-12-18`, retrieved 2026-10-26)
- Completion: 2026-06-30 (anticipated) (ClinicalTrials.gov record NCT04100148, source copy `cardio:ctgov-nct04100148-2025-12-18`, retrieved 2026-10-26)
- Countries: United States; Austria; Belgium; Canada; China; Finland; France; Germany; Hong Kong SAR China; India; Italy; Japan; Netherlands; Poland; Portugal; Puerto Rico; Russia; Saudi Arabia; Serbia; South Korea; Spain; Sweden; Taiwan; Thailand; United Kingdom (ClinicalTrials.gov record NCT04100148, source copy `cardio:ctgov-nct04100148-2025-12-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04100148-2025-12-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: SyncAV Post-Market Trial
- Acronym: SyncAV
- Condition: Congestive Heart Failure
- Intervention (Device): SyncAV programmed ON
- Intervention (Device): Fixed AV delay
- Lead sponsor: Abbott Medical Devices
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Abbott (`cardio:abbott`)

## Provenance

Content hash: dff3e8535ffb7a3a5feda59a538d8c98d1624ac4b43b97995a3c2426f3135a13
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
